期刊
LAB ON A CHIP
卷 15, 期 24, 页码 4500-4511出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5lc00947b
关键词
-
类别
资金
- National Cancer Institute (NCI)
- National Institutes of Health (NIH) [R01-CA182528]
- National Science Foundation (NSF) [DMR-1409161]
- Technological Innovation R&D Program - Small and Medium Business Administration of Korea [S2083505]
- NATIONAL CANCER INSTITUTE [R01CA182528] Funding Source: NIH RePORTER
Given the potential clinical impact of circulating tumor cells (CTCs) in blood as a clinical biomarker for the diagnosis and prognosis of various cancers, a myriad of detection methods for CTCs have been recently introduced. Among those, a series of microfluidic devices are particularly promising as they uniquely offer micro-scale analytical systems that are highlighted by low consumption of samples and reagents, high flexibility to accommodate other cutting-edge technologies, precise and well-defined flow behaviors, and automation capability, presenting significant advantages over conventional larger scale systems. In this review, we highlight the advantages of microfluidic devices and their potential for translation into CTC detection methods, categorized by miniaturization of bench-top analytical instruments, integration capability with nanotechnologies, and in situ or sequential analysis of captured CTCs. This review provides a comprehensive overview of recent advances in CTC detection achieved through application of microfluidic devices and the challenges that these promising technologies must overcome to be clinically impactful.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据